Cargando…

Differential Ca(v)2.1 and Ca(v)2.3 channel inhibition by baclofen and α-conotoxin Vc1.1 via GABA(B) receptor activation

Neuronal Ca(v)2.1 (P/Q-type), Ca(v)2.2 (N-type), and Ca(v)2.3 (R-type) calcium channels contribute to synaptic transmission and are modulated through G protein–coupled receptor pathways. The analgesic α-conotoxin Vc1.1 acts through γ-aminobutyric acid type B (GABA(B)) receptors (GABA(B)Rs) to inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Berecki, Géza, McArthur, Jeffrey R., Cuny, Hartmut, Clark, Richard J., Adams, David J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3971658/
https://www.ncbi.nlm.nih.gov/pubmed/24688019
http://dx.doi.org/10.1085/jgp.201311104
_version_ 1782309508377214976
author Berecki, Géza
McArthur, Jeffrey R.
Cuny, Hartmut
Clark, Richard J.
Adams, David J.
author_facet Berecki, Géza
McArthur, Jeffrey R.
Cuny, Hartmut
Clark, Richard J.
Adams, David J.
author_sort Berecki, Géza
collection PubMed
description Neuronal Ca(v)2.1 (P/Q-type), Ca(v)2.2 (N-type), and Ca(v)2.3 (R-type) calcium channels contribute to synaptic transmission and are modulated through G protein–coupled receptor pathways. The analgesic α-conotoxin Vc1.1 acts through γ-aminobutyric acid type B (GABA(B)) receptors (GABA(B)Rs) to inhibit Ca(v)2.2 channels. We investigated GABA(B)R-mediated modulation by Vc1.1, a cyclized form of Vc1.1 (c-Vc1.1), and the GABA(B)R agonist baclofen of human Ca(v)2.1 or Ca(v)2.3 channels heterologously expressed in human embryonic kidney cells. 50 µM baclofen inhibited Ca(v)2.1 and Ca(v)2.3 channel Ba(2+) currents by ∼40%, whereas c-Vc1.1 did not affect Ca(v)2.1 but potently inhibited Ca(v)2.3, with a half-maximal inhibitory concentration of ∼300 pM. Depolarizing paired pulses revealed that ∼75% of the baclofen inhibition of Ca(v)2.1 was voltage dependent and could be relieved by strong depolarization. In contrast, baclofen or Vc1.1 inhibition of Ca(v)2.3 channels was solely mediated through voltage-independent pathways that could be disrupted by pertussis toxin, guanosine 5′-[β-thio]diphosphate trilithium salt, or the GABA(B)R antagonist CGP55845. Overexpression of the kinase c-Src significantly increased inhibition of Ca(v)2.3 by c-Vc1.1. Conversely, coexpression of a catalytically inactive double mutant form of c-Src or pretreatment with a phosphorylated pp60c-Src peptide abolished the effect of c-Vc1.1. Site-directed mutational analyses of Ca(v)2.3 demonstrated that tyrosines 1761 and 1765 within exon 37 are critical for inhibition of Ca(v)2.3 by c-Vc1.1 and are involved in baclofen inhibition of these channels. Remarkably, point mutations introducing specific c-Src phosphorylation sites into human Ca(v)2.1 channels conferred c-Vc1.1 sensitivity. Our findings show that Vc1.1 inhibition of Ca(v)2.3, which defines Ca(v)2.3 channels as potential targets for analgesic α-conotoxins, is caused by specific c-Src phosphorylation sites in the C terminus.
format Online
Article
Text
id pubmed-3971658
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-39716582014-10-01 Differential Ca(v)2.1 and Ca(v)2.3 channel inhibition by baclofen and α-conotoxin Vc1.1 via GABA(B) receptor activation Berecki, Géza McArthur, Jeffrey R. Cuny, Hartmut Clark, Richard J. Adams, David J. J Gen Physiol Research Articles Neuronal Ca(v)2.1 (P/Q-type), Ca(v)2.2 (N-type), and Ca(v)2.3 (R-type) calcium channels contribute to synaptic transmission and are modulated through G protein–coupled receptor pathways. The analgesic α-conotoxin Vc1.1 acts through γ-aminobutyric acid type B (GABA(B)) receptors (GABA(B)Rs) to inhibit Ca(v)2.2 channels. We investigated GABA(B)R-mediated modulation by Vc1.1, a cyclized form of Vc1.1 (c-Vc1.1), and the GABA(B)R agonist baclofen of human Ca(v)2.1 or Ca(v)2.3 channels heterologously expressed in human embryonic kidney cells. 50 µM baclofen inhibited Ca(v)2.1 and Ca(v)2.3 channel Ba(2+) currents by ∼40%, whereas c-Vc1.1 did not affect Ca(v)2.1 but potently inhibited Ca(v)2.3, with a half-maximal inhibitory concentration of ∼300 pM. Depolarizing paired pulses revealed that ∼75% of the baclofen inhibition of Ca(v)2.1 was voltage dependent and could be relieved by strong depolarization. In contrast, baclofen or Vc1.1 inhibition of Ca(v)2.3 channels was solely mediated through voltage-independent pathways that could be disrupted by pertussis toxin, guanosine 5′-[β-thio]diphosphate trilithium salt, or the GABA(B)R antagonist CGP55845. Overexpression of the kinase c-Src significantly increased inhibition of Ca(v)2.3 by c-Vc1.1. Conversely, coexpression of a catalytically inactive double mutant form of c-Src or pretreatment with a phosphorylated pp60c-Src peptide abolished the effect of c-Vc1.1. Site-directed mutational analyses of Ca(v)2.3 demonstrated that tyrosines 1761 and 1765 within exon 37 are critical for inhibition of Ca(v)2.3 by c-Vc1.1 and are involved in baclofen inhibition of these channels. Remarkably, point mutations introducing specific c-Src phosphorylation sites into human Ca(v)2.1 channels conferred c-Vc1.1 sensitivity. Our findings show that Vc1.1 inhibition of Ca(v)2.3, which defines Ca(v)2.3 channels as potential targets for analgesic α-conotoxins, is caused by specific c-Src phosphorylation sites in the C terminus. The Rockefeller University Press 2014-04 /pmc/articles/PMC3971658/ /pubmed/24688019 http://dx.doi.org/10.1085/jgp.201311104 Text en © 2014 Berecki et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
spellingShingle Research Articles
Berecki, Géza
McArthur, Jeffrey R.
Cuny, Hartmut
Clark, Richard J.
Adams, David J.
Differential Ca(v)2.1 and Ca(v)2.3 channel inhibition by baclofen and α-conotoxin Vc1.1 via GABA(B) receptor activation
title Differential Ca(v)2.1 and Ca(v)2.3 channel inhibition by baclofen and α-conotoxin Vc1.1 via GABA(B) receptor activation
title_full Differential Ca(v)2.1 and Ca(v)2.3 channel inhibition by baclofen and α-conotoxin Vc1.1 via GABA(B) receptor activation
title_fullStr Differential Ca(v)2.1 and Ca(v)2.3 channel inhibition by baclofen and α-conotoxin Vc1.1 via GABA(B) receptor activation
title_full_unstemmed Differential Ca(v)2.1 and Ca(v)2.3 channel inhibition by baclofen and α-conotoxin Vc1.1 via GABA(B) receptor activation
title_short Differential Ca(v)2.1 and Ca(v)2.3 channel inhibition by baclofen and α-conotoxin Vc1.1 via GABA(B) receptor activation
title_sort differential ca(v)2.1 and ca(v)2.3 channel inhibition by baclofen and α-conotoxin vc1.1 via gaba(b) receptor activation
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3971658/
https://www.ncbi.nlm.nih.gov/pubmed/24688019
http://dx.doi.org/10.1085/jgp.201311104
work_keys_str_mv AT bereckigeza differentialcav21andcav23channelinhibitionbybaclofenandaconotoxinvc11viagababreceptoractivation
AT mcarthurjeffreyr differentialcav21andcav23channelinhibitionbybaclofenandaconotoxinvc11viagababreceptoractivation
AT cunyhartmut differentialcav21andcav23channelinhibitionbybaclofenandaconotoxinvc11viagababreceptoractivation
AT clarkrichardj differentialcav21andcav23channelinhibitionbybaclofenandaconotoxinvc11viagababreceptoractivation
AT adamsdavidj differentialcav21andcav23channelinhibitionbybaclofenandaconotoxinvc11viagababreceptoractivation